Genmab AS (LTS:0MGB) Long-Term Capital Lease Obligation : kr890 Mil (As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is Genmab AS Long-Term Capital Lease Obligation?

Genmab AS's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr890 Mil.

Genmab AS's quarterly Long-Term Capital Lease Obligation increased from Sep. 2024 (kr902 Mil) to Dec. 2024 (kr931 Mil) but then declined from Dec. 2024 (kr931 Mil) to Mar. 2025 (kr890 Mil).

Genmab AS's annual Long-Term Capital Lease Obligation increased from Dec. 2022 (kr529 Mil) to Dec. 2023 (kr690 Mil) and increased from Dec. 2023 (kr690 Mil) to Dec. 2024 (kr931 Mil).

Genmab AS Long-Term Capital Lease Obligation Historical Data

The historical data trend for Genmab AS's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Long-Term Capital Lease Obligation Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

279.99

363.68

528.65

690.05

931.05

Genmab AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															910.93	920.69	901.59	931.05	890.01

Genmab AS (LTS:0MGB) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Genmab AS Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Genmab AS's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (LTS:0MGB) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMABc:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines